First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose.
Drugs and pharma giants Pfizer...
Omicron has a substantial growth advantage over the Delta strain of COVID-19 and is rapidly replacing Delta globally, particularly because it is able to...
Relying solely on the Chinese-manufactured Sinovac inactive vaccine is not enough to reduce transmission rates of COVID-19. Millions of people in 48 countries around...
Timely community action and strengthened health services will determine how many more young lives are placed at risk before cooler weather arrives, health workers say.